We are live on ! Find out more

State Street SPDR S&P Biotech ETF

XBI

Market cap $10B

144.32 USD

-5.46

3.65%

At close Updated Oct 16, 4:00 PM EDT

Pre-market

After hours

145.01

+0.69

0.48%

1 day

-3.65%

5 days

-5.94%

1 month

-6.4%

3 months

-5.05%

6 months

6.54%

Year to date

18.76%

1 year

33.74%

5 years

17.84%

10 years

144.32%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60.7%

Neutral 25%

Negative 14.3%

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

From Laggard to Leader: The Surprising Comeback of Healthcare

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

From Laggard to Leader: The Surprising Comeback of Healthcare

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Pharmaceutical trade group sues Trump administration

Pharmaceutical Research and Manufacturers of ‌America, the pharmaceutical industry lobbying group, sued the ⁠Trump administration on Wednesday, court records show.

Pharmaceutical trade group sues Trump administration

CNBC Television

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

The Motley Fool

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF experienced a much deeper maximum drawdown over the last five years but outperformed on a 1-year total return basis.

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

The Motley Fool

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

Zacks Investment Research

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Biotech: The Party's Over, The Top Is In

The State Street SPDR S&P Biotech ETF has likely peaked after a 60% rally over the past year. Key tailwinds—practice-changing drug approvals, pharma M&A, and lower rates—have faded as the rate cycle has reversed. Equity supply in biotech is at cycle peak levels, signaling potential headwinds for further upside.

Biotech: The Party's Over, The Top Is In

The Motley Fool

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?

VHT offers significantly lower ownership costs, with a 0.09% expense ratio compared to XBI's 0.35%. XBI provides targeted focus on biotechnology, while VHT offers exposure to the entire healthcare sector.

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?

See News Rankings

Price charts implemented using Lightweight Charts™